Correction to: Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAntifungal resistance and susceptibility
This is a correction to: Barbara D Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven, Belinda Lovelace, Craig I Coleman, Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis, Open Forum Infectious Diseases, Volume 12, Issue 1, January 2025, ofae747, https://doi.org/10.1093/ofid/ofae747
In the originally published version of the manuscript there was an error in Table 2. In Table 2, the median total cost (in $) value for patients who changed antifungal therapy is emended to read: “149 007” instead of: “14 900”.